Status:
COMPLETED
Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases
Lead Sponsor:
University of Hawaii
Collaborating Sponsors:
Charles Drew University of Medicine and Science
Meharry Medical College
Conditions:
Breakthrough Bleeding
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
The purpose of this study is to compare the effects (good and bad) of subantimicrobial dose doxycycline on the irregular bleeding women experience when taking continuous oral contraceptive pills. This...
Detailed Description
Continuous oral contraceptive administration entails women taking hormonally active pills for 28 days without a seven day placebo week to avoid hormonal withdrawal bleeding. Unfortunately, with contin...
Eligibility Criteria
Inclusion
- Women between the ages 18 and 45 who are ovulatory as demonstrated by a pre-treatment Progesterone (P) greater than or equal to 3.0 ng/mL prior to oral contraceptive use
Exclusion
- Women with any absolute contraindications to ethinyl estradiol and levonorgestrel;
- Women who are pregnant or breastfeeding
- Use of oral contraceptives, patch, ring, intrauterine or implantable hormonal contraception within 4-weeks;
- Medroxyprogesterone acetate use within six months;
- Current use of drugs that interfere with sex steroid metabolism.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01469585
Start Date
November 1 2011
End Date
May 1 2012
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, United States, 96826